(XPH) SPDR S&P Pharmaceuticals - Ratings and Ratios
Pharmaceuticals, Biotechnology, Generic, Specialty, Research
Dividends
| Dividend Yield | 0.90% |
| Yield on Cost 5y | 1.09% |
| Yield CAGR 5y | 29.03% |
| Payout Consistency | 91.0% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 20.6% |
| Value at Risk 5%th | 34.1% |
| Relative Tail Risk | 0.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.93 |
| Alpha | 13.88 |
| CAGR/Max DD | 0.53 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.534 |
| Beta | 0.729 |
| Beta Downside | 0.833 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.57% |
| Mean DD | 6.91% |
| Median DD | 6.20% |
Description: XPH SPDR S&P Pharmaceuticals November 15, 2025
The SPDR S&P Pharmaceuticals ETF (ticker XPH) seeks to replicate the S&P Pharmaceuticals Select Industry Index by using a sampling approach, allocating at least 80 % of its assets to the index constituents. The index captures the pharmaceutical slice of the broader S&P Total Market Index, giving investors exposure to large-cap U.S. drug makers.
Key metrics as of the latest filing show an expense ratio of roughly 0.35 % and assets under management near $1.2 billion. The fund’s top holdings typically include Johnson & Johnson, Pfizer and Merck, together representing over 30 % of the portfolio. Sector fundamentals are driven by an aging global population, sustained R&D pipelines, and regulatory dynamics such as FDA approval rates and drug-pricing policies, which together set the growth outlook for U.S. pharma revenues.
For a deeper dive into XPH’s valuation nuances and risk profile, you might explore the detailed metrics on ValueRay.
What is the price of XPH shares?
Over the past week, the price has changed by +3.48%, over one month by +10.49%, over three months by +21.24% and over the past year by +27.77%.
Is XPH a buy, sell or hold?
What are the forecasts/targets for the XPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 57.8 | 2.8% |
XPH Fundamental Data Overview December 09, 2025
Beta = 0.91
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 220.5m USD (220.5m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 220.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 220.5m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.70% (E(220.5m)/V(220.5m) * Re(8.70%) + (debt-free company))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for XPH ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle